{ }
The US economy shows signs of slowing, prompting the Fed to cut rates by 50bp, with expectations for further cuts in 2024. In Europe, the ECB's recent rate cut reflects weak growth and inflation progress, while China’s stimulus measures aim to stabilize growth amid economic challenges. Investment opportunities arise in high-quality credit and emerging markets, particularly in Asia, as monetary easing continues globally.
21:02 21.10.2024
The US economy shows signs of slowing, prompting the Fed to cut rates by 50bp, with expectations for further cuts in 2024. In Europe, the ECB's recent rate cut reflects weak growth and inflation trends, while China’s stimulus measures aim to stabilize its economy and support a 5% GDP growth target for 2024. Investment opportunities arise in high-quality credit and emerging markets, particularly in Asia, as monetary easing continues globally.
21:02 21.10.2024
The US economy shows signs of slowing, prompting the Fed to cut rates by 50bp, with expectations for further cuts in 2024. In Europe, the ECB's easing reflects weak growth and inflation, while China’s recent stimulus aims to stabilize its economy and achieve 5% GDP growth for 2024. Investment opportunities arise in high-quality credits and emerging markets, particularly in Asia, as monetary policies become less restrictive.
21:02 21.10.2024
The US economy shows signs of slowing, prompting the Fed to cut rates by 50bp, with expectations for further cuts in 2024. In Europe, the ECB's recent rate cut reflects weak growth and inflation progress, while China’s stimulus measures aim to stabilize growth amid economic challenges. Investment opportunities arise in high-quality credit and emerging markets, particularly in Asia, as monetary easing continues globally.
21:02 21.10.2024
The US economy shows strength despite labor market weaknesses, prompting a 50bp Fed rate cut, with expectations for further cuts in 2024. In Europe, the ECB's easing reflects weak growth and inflation, while China's recent stimulus aims to stabilize its economy and achieve 5% GDP growth for 2024. Investment opportunities arise in high-quality credit and emerging markets, particularly in Asia, as monetary policies become less restrictive.
21:02 21.10.2024
The US economy shows signs of slowing, prompting the Fed to cut rates by 50bp, with expectations for further cuts in 2024. In Europe, the ECB's recent rate cut reflects weak growth and inflation trends, while China’s stimulus measures aim to stabilize its economy and achieve 5% GDP growth in 2024. Investment opportunities arise in high-quality credits and emerging markets, particularly in Asia, as monetary easing continues globally.
21:02 21.10.2024
The outlook for global equities is improving, driven by a global rate-cutting cycle, strong earnings, and resilient growth. The US market, particularly in technology, is deemed attractive, while smaller European stocks and Asian ex-Japan equities present near-term opportunities. Earnings growth is expected to be robust, with forecasts indicating significant growth in both the US and India.
17:53 21.10.2024
Donald Trump's proposed tariffs, including a 10% tax on imports, are expected to burden American consumers, costing middle-class households over $2,600 annually and leading to a loss of prosperity. While intended to boost domestic production and jobs, historical evidence suggests that tariffs often result in high costs for minimal job creation, with indirect effects harming other industries reliant on imported materials.
Chinese stimulus measures are seen as a positive yet modest step to revitalize the economy, with the People's Bank of China recently cutting lending rates. UBS has raised its GDP forecast for China to 4.8%, still below the government's 5% target, while highlighting ongoing challenges in the property sector and manufacturing overcapacity. Analysts recommend a tactical overweight in Chinese equities, citing their value and improving earnings revisions, while expressing caution towards luxury stocks and US consumer brands exposed to China's economic issues.
14:00 21.10.2024
JiangSu WuZhong Pharmaceutical Development Co., Ltd. reported a significant increase in earnings for the nine months ended September 30, 2024, with sales reaching CNY 1,647.31 million, up from CNY 1,503.35 million the previous year. Net income rose to CNY 45.08 million, compared to CNY 10.95 million a year ago, resulting in basic and diluted earnings per share from continuing operations of CNY 0.063, up from CNY 0.015.
Trending
Subcategory:
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.